Staufen1 in Human Neurodegeneration

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Mutations in the ATXN2 gene are linked to rare forms of Parkinson's disease and ALS.
• Overabundance of the stress granule (SG) protein Staufen1 (STAU1) was previously observed in spinocerebellar ataxia type 2 (SCA2) and ALS patient cells.
• A connection between SG formation and autophagy has been established.

Purpose of the Study:

• To investigate the role of STAU1 overabundance in the pathogenesis of various neurodegenerative diseases.
• To determine if STAU1 overabundance is a common feature across different neurodegenerative conditions.
• To explore the therapeutic potential of targeting STAU1.

Main Methods:

• Utilized multiple neurodegenerative patient-derived cell models and animal models.
• Employed biochemical and immunohistological analyses on patient cells, animal models, and human postmortem ALS tissue.
• Assessed STAU1 function and its relationship with mTOR signaling.

Main Results:

• Demonstrated STAU1 overabundance and increased mammalian target of rapamycin (mTOR) activity in patient cells with ALS (TDP-43), dementia (PSEN1), parkinsonism (MAPT), Huntington's disease, and SCA2.
• Observed elevated STAU1 levels and mTOR activity in human ALS spinal cord tissues and animal models.
• Confirmed that exogenous STAU1 expression activates mTOR and SG formation, and RNAi targeting STAU1 normalized mTOR.

Conclusions:

• STAU1 overabundance is a shared characteristic of neurodegenerative diseases, associated with hyperactive mTOR signaling.
• Targeting STAU1 using antisense oligonucleotides (ASOs) or miRNA viral vectors presents a potential therapeutic strategy.
• This approach may offer a novel and effective treatment for neurodegenerative diseases characterized by elevated STAU1 levels.